Showing 2351-2360 of 5771 results for "".
- EyePoint Pharmaceuticals Announces US Commercial Launch of Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-us-commercial-launch-of-dexycu/2476370/EyePoint Pharmaceuticals announced that it has commercially launched Dexycu (dexamethasone intraocular suspension) 9% in the United States. Dexycu is the first and only FDA approved intraocular steroid for the treatment of postoperative inflammation and is administered as a single dose at the end
- BioTime Announces Closing of Acquisition of Asterias Biotherapeuticshttps://modernod.com/news/biotime-announces-closing-of-acquisition-of-asterias-biotherapeutics/2476362/BioTime announced the closing of its previously reported acquisition of Asterias Biotherapeutics, whereby BioTime has acquired through a merger, all of the remaining outstanding common stock of Asterias which was not previously owned by BioTime. As a result of the acquisition, Asterias became a w
- Major League Soccer All-Star Alecko Eskandarian to Speak at Annual NORA Conferencehttps://modernod.com/news/major-league-soccer-all-star-alecko-eskandarian-to-speak-at-annual-nora-conference/2476364/Two-time Major League Soccer (MLS) All-Star Alecko Eskandarian will be the key-note speaker at the Neuro-Optometric Rehabilitation Association, International (NORA) 28th annual General Conference (September 21-22) at the Embassy Suites by Hilton Scottsdale Resorts, Scottsdale, Arizona.
- Staar Surgical Announces Strategic Cooperation Agreement with Vista Oftalmólogoshttps://modernod.com/news/staar-surgical-announces-strategic-cooperation-agreement-with-vista-oftalmologos/2479594/Staar Surgical Company announced a strategic cooperation agreement with Vista Oftalmólogos, a 49-clinic ophthalmology group spanning Spain, France, Portugal, and Morocco with more than 200 eye doctors and 1,000 employees. The agreement positions the EVO Visian ICL family of lenses as a premium an
- TopiVert Announces First Patients Dosed in THEIA-1 Phase 2b/3 Study of Dry Eye Disease Treatmenthttps://modernod.com/news/topivert-announces-first-patients-dosed-in-theia-1-phase-2b-3-study-of-dry-eye-disease-treatment/2476259/TopiVert Pharma announced that the first patients have been dosed in the THEIA-1 phase 2b/3 clinical study evaluating TOP1630, a novel anti-inflammatory kinase inhibitor, as an ophthalmic solution for the treatment of dry eye disease. THEIA-1 is a multicenter, randomised, double-masked, pl
- Eyenovia Announces Confirmatory Results from Second MicroStat Phase 3 Registration Study for Mydriasishttps://modernod.com/news/eyenovia-announces-confirmatory-results-from-second-microstat-phase-3-registration-study-for-mydriasis/2476266/Eyenovia announced positive results from its second MicroStat phase 3 study, MIST-2, which examined the safety and efficacy of the company’s first-in-class MicroStat fixed-combination formulation for pharmacologic mydriasis. The MIST-2 study was a US-based, multicenter, randomized, double-
- EyeBrain Medical and IDOC Announce Partnership to Bring Neurolens to IDOC Independent Optometristshttps://modernod.com/news/eyebrain-medical-and-idoc-announce-partnership-to-bring-neurolens-to-idoc-independent-optometrists/2476270/IDOC and eyeBrain Medical announced a multiyear partnership to bring neurolens prescription lenses to all IDOC members across the United States. Neurolenses are the first and only prescription lenses that add a contoured prism to bring the eyes into alignment. Contoured prisms have been shown in
- Ocular Therapeutix Announces Dosing of First Patient in Phase 1 Clinical Trial for the Treatment of Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-dosing-of-first-patient-in-phase-1-clinical-trial-for-the-treatment-of-wet-amd/2476273/Ocular Therapeutix announced the dosing of the first patient in a phase 1 trial of OTX-TKI (tyrosine kinase inhibitor implant) in patients with wet age-related macular degeneration (AMD). The first patient was dosed at the Sydney Retina Clinic in Sydney, Australia. “We are excited to annou
- ReNeuron Group Announces Positive Preliminary Data in US Retinitis Pigmentosa Trialhttps://modernod.com/news/reneuron-group-announces-positive-preliminary-data-in-us-retinitis-pigmentosa-trial/2476276/ReNeuron Group announced positive preliminary results in the company’s ongoing phase 1/2 clinical trial of its human retinal progenitor cells (hRPC) cell therapy candidate in retinitis pigmentosa (RP). All three subjects in the first cohort of the phase 2 part of the trial have demonstrate
- Alembic Pharmaceuticals Announces FDA Approval for Glaucoma Treatment Acetazolamidehttps://modernod.com/news/alembic-pharmaceuticals-announces-fda-approval-for-glaucoma-treatment-acetazolamide-extended-release-capsules/2476277/India-based Alembic Pharmaceuticals announced that it has received approval from the FDA for its abbreviated new drug application (NDA) for Acetazolamide extended-release capsules, 500 mg. The approved NDA is therapeutically equivalent to the reference listed drug product Diamox Sequels, 500 mg,